From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 2
Abstract
The online version of this article (doi:10.1208/s12248-011-9256-y) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Jing Yu, Helene Karcher, Adam L. Feire, Philip J. Lowe
Keywords
Related Articles
- EP ID EP681301
- DOI 10.1208/s12248-011-9256-y
- Views 119
- Downloads 0
Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist
Taranabant is a cannabinoid-1 receptor inverse agonist developed for the treatment of obesity. A population model was constructed to facilitate the estimation of pharmacokinetic parameters and to identify the influence o...
Commentary: Drug hypersensitivity—Where do we stand?
Mechanistic Modeling of Monocarboxylate Transporter-Mediated Toxicokinetic/Toxicodynamic Interactions Between γ-Hydroxybutyrate and l -Lactate
Overdose of γ-hydroxybutyrate (GHB) can result in severe respiratory depression. Monocarboxylate transporter (MCT) inhibitors, including l -lactate, increase GHB clearance and represent a potential treatment for...
Neuro-fuzzy Models as an IVIVR Tool and Their Applicability in Generic Drug Development
The online version of this article (doi:10.1208/s12248-014-9569-8) contains supplementary material, which is available to authorized users.
Erratum to: Autoradiography, MALDI-MS, and SIMS-MS Imaging in Pharmaceutical Discovery and Development
This article was published with incorrect reference citations in the permission notes in the legends for Figures  8 and 9. The permission note for Figure 8 should read: (Adapted with permission from Ref....